Cargando…

Comparison of two endogenous biomarkers of CYP3A4 activity in a drug–drug interaction study between midostaurin and rifampicin

PURPOSE: Midostaurin, a multitargeted tyrosine kinase inhibitor, is primarily metabolized by CYP3A4. This midostaurin drug–drug interaction study assessed the dynamic response and clinical usefulness of urinary 6β-hydroxycortisol to cortisol ratio (6βCR) and plasma 4β-hydroxycholesterol (4βHC) for m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dutreix, Catherine, Lorenzo, Sebastien, Wang, Yanfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088993/ https://www.ncbi.nlm.nih.gov/pubmed/24839948 http://dx.doi.org/10.1007/s00228-014-1675-0

Ejemplares similares

Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers
por: Dutreix, Catherine, et al.
Publicado: (2013)

Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers
por: del Corral, Adam, et al.
Publicado: (2012)

Drug–drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer
por: Park, Gab-jin, et al.
Publicado: (2017)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates
por: Haberer, Lynda J., et al.
Publicado: (2013)

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
por: Azuma, Junichi, et al.
Publicado: (2011)

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies
por: Bolleddula, Jayaprakasam, et al.
Publicado: (2022)

The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers
por: Schneider, F., et al.
Publicado: (2021)

Effects of the Glaucoma Drugs Latanoprost and Brimonidine on Corneal Temperature
por: Konieczka, Katarzyna, et al.
Publicado: (2019)

Safety and Comfort of an Innovative Drug Delivery Device in Healthy Subjects
por: Bertens, Christian J. F., et al.
Publicado: (2020)

Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro Data
por: Yamashita, Fumiyoshi, et al.
Publicado: (2013)

Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low
por: Heinonen, E., et al.
Publicado: (2021)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole
por: Lunardi, G., et al.
Publicado: (2012)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients
por: Thorén, Linda, et al.
Publicado: (2021)

2432: A close examination of anti-retroviral drug selection and management in the optima study
por: Huang, Yuan, et al.
Publicado: (2018)

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
por: Rabinovich‐Guilatt, L., et al.
Publicado: (2015)

Gut Microbiota Participates in Antithyroid Drug Induced Liver Injury Through the Lipopolysaccharide Related Signaling Pathway
por: Sun, Jiayu, et al.
Publicado: (2020)

73936 Developing a Patient-Rated Outcome Measure of Alcohol and Drug Craving: A Systematic Review
por: Haeny, Angela M., et al.
Publicado: (2021)

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment
por: Zhao, Baiteng, et al.
Publicado: (2016)

P586: POTENTIAL DRUG-DRUG INTERACTIONS OF ANTIFUNGAL PROPHYLAXIS AND MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA – CLINICAL IMPLICATIONS OF THERAPEUTIC DRUG MONITORING
por: Joisten, Carolin, et al.
Publicado: (2023)

Two-Year Outcomes of Cochlear Implant Use for Children With Unilateral Hearing Loss: Benefits and Comparison to Children With Normal Hearing
por: Park, Lisa R., et al.
Publicado: (2023)

Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation
por: Li, Yang, et al.
Publicado: (2021)

Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria
por: Darpo, Borje, et al.
Publicado: (2015)

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug‐Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects
por: Asaumi, Ryuta, et al.
Publicado: (2018)

Physiologically‐Based Pharmacokinetic Models for CYP1A2 Drug–Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam
por: Britz, Hannah, et al.
Publicado: (2019)

Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients
por: Nteliopoulos, Georgios, et al.
Publicado: (2021)

Patterns of drug prescriptions in an orthogeriatric ward as compared to orthopaedic ward: results from the Trondheim Hip Fracture Trial—a randomised clinical trial
por: Heltne, Marianne, et al.
Publicado: (2017)

A complementary new drug for PNH
por: Brodsky, Robert A.
Publicado: (2020)

Clinical evaluation of the potential drug–drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam
por: Ren, Song, et al.
Publicado: (2021)

Comparison of Two Different Intravitreal Injection Techniques
por: Uy, Harvey S, et al.
Publicado: (2021)

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
por: Martin, Paul, et al.
Publicado: (2012)

Drug-resistant Hypertension: Is Renal Sympathetic Denervation the Answer?
por: Thompson, Keith A., et al.
Publicado: (2011)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
por: McFarthing, Kevin, et al.
Publicado: (2020)

Impact of dementia and drug compliance on patients with acute myocardial infarction
por: Lee, Wonjae, et al.
Publicado: (2023)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update
por: McFarthing, Kevin, et al.
Publicado: (2021)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update
por: McFarthing, Kevin, et al.
Publicado: (2022)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
por: McFarthing, Kevin, et al.
Publicado: (2023)

Expanded Physiologically‐Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction
por: Asaumi, Ryuta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dte2htfm80i5sl5vv66v9l6u66